US and European private VC-backed orphan biopharma company M&A values 2014-2019
In 2016, the transaction volumes of private biopharma companies that do not product orphan products reached 19.6 billion U.S. dollars, whereas the values for companies that produce orphan products was 1.3 billion U.S. dollars. This statistic shows the M&A transaction volumes of private venture capital-backed orphan biopharma companies in U.S. and Europe from 2014 to 2019.